CytoMed Therapeutics (GDTC) analyst forecast and price target
Analyst forecast
Consensus of 1 analyst rating
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Benchmark | Maintained | Speculative Buy | $5.00 | Oct 10, 2024 |
| Benchmark | Maintained | Speculative Buy | $5.00 | Jun 11, 2024 |
| Benchmark | Maintained | Speculative Buy | $5.00 | Dec 4, 2023 |
| Benchmark | Initiated Coverage | Speculative Buy | $5.00 | Jul 21, 2023 |
Frequently asked questions
Is GDTC a buy, sell, or hold?
Analysts covering CytoMed Therapeutics currently average a Buy rating: 1 buy, 0 hold and 0 sell, from 1 analyst. Ratings reflect analyst opinion, not investment advice.
What is the latest analyst rating on GDTC?
On Oct 10, 2024, Benchmark maintained CytoMed Therapeutics at Speculative Buy with a price target of $5.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.